Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APL-1202 plus tislelizumab as neoadjuvant therapy in muscle-invasive bladder cancer
CTR20220292Phase 2Completed
- Sponsor
- Asieris Pharmaceuticals
- Start
- Feb 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of APL-1202 + APL-1501, tislelizumab in muscle-invasive bladder carcinoma (MIBC), sponsored by Asieris Pharmaceuticals. Started Feb 2022; status: completed.
02
Drugs
APL-1202 + APL-1501tislelizumab
03
Conditions
muscle-invasive bladder carcinoma (MIBC)
Beyond the preview
Go deeper on CTR20220292.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220292.